ClinicalTrials.gg
CompletedNCT02186171BRIDGEUpdated May 28, 2019Results posted

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

A Phase 3 interventional study of Romosozumab and Placebo in Osteoporosis in Men, sponsored by Amgen. Completed at 34 sites in 10 countries. Open to male participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-05-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Enrollment
6th of 20
245 · median 80
Started
2014
the only one that year
Phase 3
5 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
8 of 20
Amgen

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 6th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

The study is designed to evaluate if treatment with romosozumab once a month for 12 months compared with placebo is effective in increasing bone mineral density (BMD) at the lumbar spine. Additionally, the study will assess the effect of treatment with romosozumab for 12 months compared with placebo on BMD at the femoral neck and total hip.

03

Conditions studied

  • Osteoporosis in Men

Browse trials for

Keywords

  • Osteoporosis in men
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age
  • Must have a BMD T score ≤ -2.50 at the spine or hip, or BMD T score ≤ -1.50 at the spine or hip and a history of fragility nonvertebral fracture or vertebral fracture.

Exclusion criteria

Exclusion Criteria:

  • A BMD T score ≤ -3.50 at the hip,
  • History of hip fracture
  • Severe metabolic bone diseases
  • Significant laboratory abnormalities
  • Recent treatment with agents affecting bone metabolism
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Romosozumab

    Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.

    Biological: Romosozumab

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injections once a month for 12 months.

    Drug: Placebo

Interventions

  • BiologicalRomosozumab

    Administered by subcutaneous injection once a month.

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo

    Administered by subcutaneous injection once a month.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12

    Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 12

Secondary outcomes

  1. Percent Change From Baseline in BMD at the Total Hip at Month 12

    Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 12

  2. Percent Change From Baseline in BMD at the Femoral Neck at Month 12

    Femoral neck bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 12

  3. Percent Change From Baseline in Lumbar Spine BMD at Month 6

    Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 6

  4. Percent Change From Baseline in BMD at the Total Hip at Month 6

    Bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 6

  5. Percent Change From Baseline in BMD at the Femoral Neck at Month 6

    Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and month 6

07

Results

Posted May 28, 2019

Participant flow

This study was conducted at 31 centers in Europe, North America, Latin America, and Japan. Participants were enrolled from 16 June 2014 to 27 January 2015.

Participant flow — Overall Study
MilestonePlaceboRomosozumab 210 mg
Started82163
Received treatment81163
Completed78148
Not completed415
Withdrew: Withdrawal by subject19
Withdrew: Lost to follow-up22
Withdrew: Death12
Withdrew: Protocol-specified criteria02

Outcome measures

PrimaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12

Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 121.2 ± 0.512.1 ± 0.5
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = < 0.0001 (ANCOVA model adjusting for treatment, baseline BMD value, machine type, machine type-by-baseline BMD value, baseline testosterone level, geographic region, and using a variance structure allowing for heterogeneity between treatment groups.) · Ls mean difference: 10.9 · 95% CI 9.6 to 12.2
SecondaryPercent Change From Baseline in BMD at the Total Hip at Month 12

Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in BMD at the Total Hip at Month 12
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline in BMD at the Total Hip at Month 12-0.5 ± 0.32.5 ± 0.2
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = < 0.0001 (ANCOVA model adjusting for treatment, baseline BMD value, machine type, machine type-by-baseline BMD value, baseline testosterone level, geographic region, and using a variance structure allowing for heterogeneity between treatment groups.) · Ls mean difference: 3.0 · 95% CI 2.3 to 3.7
SecondaryPercent Change From Baseline in BMD at the Femoral Neck at Month 12

Femoral neck bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in BMD at the Femoral Neck at Month 12
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline in BMD at the Femoral Neck at Month 12-0.2 ± 0.42.2 ± 0.4
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = < 0.0001 (ANCOVA model adjusting for treatment, baseline BMD value, machine type, machine type-by-baseline BMD value, baseline testosterone level, geographic region, and using a variance structure allowing for heterogeneity between treatment groups.) · Ls mean difference: 2.4 · 95% CI 1.5 to 3.3
SecondaryPercent Change From Baseline in Lumbar Spine BMD at Month 6

Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lumbar Spine BMD at Month 6
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline in Lumbar Spine BMD at Month 60.3 ± 0.49.0 ± 0.4
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = < 0.0001 (ANCOVA model adjusting for treatment, baseline BMD value, machine type, machine type-by-baseline BMD value, baseline testosterone level, geographic region, and using a variance structure allowing for heterogeneity between treatment groups.) · Ls mean difference: 8.7 · 95% CI 7.6 to 9.7
SecondaryPercent Change From Baseline in BMD at the Total Hip at Month 6

Bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in BMD at the Total Hip at Month 6
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline in BMD at the Total Hip at Month 60.2 ± 0.21.6 ± 0.2
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = < 0.0001 (ANCOVA model adjusting for treatment, baseline BMD value, machine type, machine type-by-baseline BMD value, baseline testosterone level, geographic region, and using a variance structure allowing for heterogeneity between treatment groups.) · Ls mean difference: 1.4 · 95% CI 0.8 to 2.0
SecondaryPercent Change From Baseline in BMD at the Femoral Neck at Month 6

Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in BMD at the Femoral Neck at Month 6
percent changePlaceboRomosozumab 210 mg
Percent Change From Baseline in BMD at the Femoral Neck at Month 60.0 ± 0.41.2 ± 0.3
Statistical analysis
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = = 0.0033 (ANCOVA model adjusting for treatment, baseline BMD value, machine type, machine type-by-baseline BMD value, baseline testosterone level, geographic region, and using a variance structure allowing for heterogeneity between treatment groups.) · Ls mean difference: 1.3 · 95% CI 0.4 to 2.1

Adverse events

Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—10/81 (12.3%)41/81 (50.6%)
Romosozumab 210 mg—23/163 (14.1%)74/163 (45.4%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventPlaceboRomosozumab 210 mg
Atrial fibrillationCardiac disorders1/810/163
Atrial flutterCardiac disorders1/811/163
Cardiac valve diseaseCardiac disorders1/810/163
Abdominal painGastrointestinal disorders1/810/163
Abdominal pain upperGastrointestinal disorders1/810/163
Intra-abdominal haemorrhageGastrointestinal disorders1/810/163
DeathGeneral disorders1/811/163
Non-cardiac chest painGeneral disorders1/811/163
Atypical pneumoniaInfections and infestations1/810/163
Pneumonia bacterialInfections and infestations1/810/163
Most frequent other events
Most frequent other events
EventPlaceboRomosozumab 210 mg
NasopharyngitisInfections and infestations22/8135/163
ArthralgiaMusculoskeletal and connective tissue disorders8/8110/163
Back painMusculoskeletal and connective tissue disorders4/8115/163
HypertensionVascular disorders5/8114/163
Procedural painInjury, poisoning and procedural complications6/818/163
HeadacheNervous system disorders6/8110/163
Muscle spasmsMusculoskeletal and connective tissue disorders5/813/163
MyalgiaMusculoskeletal and connective tissue disorders5/814/163
ConstipationGastrointestinal disorders1/819/163

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomosozumab 210 mgTotal
Mean71.5 ± 6.972.4 ± 7.472.1 ± 7.3
Age, Customized
Age, Customized(Participants)PlaceboRomosozumab 210 mgTotal
18 - 64 years113142
65 - 74 years4262104
75 years and over297099
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumab 210 mgTotal
Female000
Male82163245
Race
Race(Participants)PlaceboRomosozumab 210 mgTotal
White60120180
Asian91827
Black or African American011
Other132336
Multiple011
Geographic Region
Geographic Region(Participants)PlaceboRomosozumab 210 mgTotal
Europe54108162
Japan91827
Latin America122335
North America71421
Lumbar Spine Bone Mineral Density T-score
Lumbar Spine Bone Mineral Density T-score(T-score)PlaceboRomosozumab 210 mgTotal
Mean-2.33 ± 1.41-2.22 ± 1.19-2.26 ± 1.27
Total Hip BMD T-score
Total Hip BMD T-score(T-score)PlaceboRomosozumab 210 mgTotal
Mean-1.92 ± 0.65-1.92 ± 0.59-1.92 ± 0.61
Femoral Neck BMD T-score
Femoral Neck BMD T-score(T-score)PlaceboRomosozumab 210 mgTotal
Mean-2.30 ± 0.52-2.34 ± 0.52-2.33 ± 0.52
08

Study locations

34 sites
  • Research Site
    Lakewood, Colorado 80227, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Albuquerque, New Mexico 87106, United States
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4020, Belgium
  • Research Site
    Medellin, Antioquia 050021, Colombia
  • Research Site
    Bogota, Cundinamarca 11001000, Colombia
  • Research Site
    Ostrava-Trebovice, 722 00, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 11 - Chodov, 148 00, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Mizunami-shi, Gifu 509-6134, Japan
  • Research Site
    Yokohama-shi, Kanagawa 223-0062, Japan
  • Research Site
    Bungoono-shi, Oita 879-7125, Japan
  • Research Site
    Takatsuki-shi, Osaka 569-1123, Japan
  • Research Site
    Hachioji-shi, Tokyo 192-0046, Japan
  • Research Site
    Shinagawa-ku, Tokyo 140-0011, Japan
  • Research Site
    Toshima-ku, Tokyo 171-0033, Japan
  • Research Site
    Mexicali, Baja California Norte 21100, Mexico
  • Research Site
    Monterrey, Nuevo León 64460, Mexico
  • Research Site
    Culiacan, Sinaloa 80000, Mexico
  • Research Site
    Lodz, 90-558, Poland
  • Research Site
    Swidnik, 21-040, Poland
  • Research Site
    Warszawa, 01-192, Poland
  • Research Site
    Wroclaw, 50-088, Poland
  • Research Site
    Moscow, 101990, Russian Federation
  • Research Site
    Saint-Petersburg, 190103, Russian Federation
  • Research Site
    Yaroslavl, 150003, Russian Federation
  • Research Site
    Bern, 3010, Switzerland
  • Research Site
    Zurich, 8063, Switzerland
  • Research Site
    Zurich, 8091, Switzerland
09

References and documents

Publications

  • Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193. doi: 10.1210/jc.2017-02163. PubMed 29931216 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Feb 2016, 19 months.

Results were first posted in May 2019, 3 years 3 months after primary completion. A results delay was requested in Sep 2016.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 19 months is below that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2014
First posted
Jul 10, 2014
StartActual
Jun 16, 2014
Primary completionActual
Feb 15, 2016
CompletionActual
Apr 20, 2016
Results delay requested
Sep 26, 2016
Results first posted
May 28, 2019
Last update
May 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02186171
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 10, 2014
Start date
Jun 16, 2014
Primary completion
Feb 15, 2016
Completion
Apr 20, 2016
Results posted
May 28, 2019
Last update
May 28, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion